News & Updates

Exercise enhances glycaemic control in T1D
Exercise enhances glycaemic control in T1D
02 Jun 2023
Attention bias modification treatment eases symptoms in social anxiety disorder
Attention bias modification treatment eases symptoms in social anxiety disorder
01 Jun 2023

People with social anxiety disorder (SAD) may benefit from gaze-contingent music reward therapy (GC-MRT), an eye-tracking-based attention bias modification treatment, which has been shown to reduce SAD symptoms in a recent study.

Attention bias modification treatment eases symptoms in social anxiety disorder
01 Jun 2023
Influenza linked to neurologic comorbidities in children
Influenza linked to neurologic comorbidities in children
01 Jun 2023

Influenza in a paediatric population can manifest as a neurologic disease, particularly as febrile seizures, according to a study. Hospitalized children with neurologic manifestation of influenza (neuro-flu) experience several neurologic comorbidities, which suggest that this condition is driven by host-factors rather than by pathogen-factors.

Influenza linked to neurologic comorbidities in children
01 Jun 2023
Genetically predicted depression linked to multiple gastrointestinal disorders
Genetically predicted depression linked to multiple gastrointestinal disorders
31 May 2023

Genetic predisposition to major depressive disorder has the potential to increase the risk of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcer disease, and nonalcoholic fatty liver disease (NAFLD), according to the results of a Mendelian randomization study.

Genetically predicted depression linked to multiple gastrointestinal disorders
31 May 2023
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
31 May 2023 byJairia Dela Cruz

Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.

First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
31 May 2023
Cytokine profile tied to treatment response in eczematous dermatitis
Cytokine profile tied to treatment response in eczematous dermatitis
31 May 2023

The baseline skin cytokine profile of patients with eczematous dermatitis, as determined by RNA in situ hybridization, can help predict response to dupilumab therapy, results of a study have shown.

Cytokine profile tied to treatment response in eczematous dermatitis
31 May 2023